MedTrace Logo

Real-world Evidence Prospective Study on the Effect of Nab-paclitaxel Treatment on the Clinical Outcomes and HRQoL in Patients With MBC in Greece

NCT02626013 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 156

Last updated 2020-11-30

No results posted yet for this study

Summary

This non-interventional study aims at assessing the impact of nab-paclitaxel on the clinical outcomes and the health-related QoL (HRQoL) of this heavily burdened and difficult-to-treat population. Notably, the data generated in the context of this study will serve as complementary evidence to that of the tightly and strictly controlled pre-registration clinical trial setting, which is of essential importance especially in patient populations with diseases of complex and heterogeneous biology, such as breast cancer.

Conditions

Sponsors & Collaborators

  • Genesis Pharma S.A.

    lead INDUSTRY

Principal Investigators

  • Kiki Karvounis · GenesisPharma Medical Department

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-12
Primary Completion
2018-09-12
Completion
2018-09-12

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02626013 on ClinicalTrials.gov